GANX
Income statement / Annual
Last year (2025), Gain Therapeutics Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Gain Therapeutics Inc's net income was -$20.16 M.
See Gain Therapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$0.00 |
$0.00 |
$55.18 K |
$132.64 K |
$133.93 K |
$28.88 K |
$41.30 K |
$20.61 K |
| Cost of Revenue |
$94.05 K
|
$0.00
|
$0.00
|
$8.24 M
|
$7.16 M
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
-$94.05 K
|
$0.00
|
$55.18 K
|
-$8.11 M
|
-$7.03 M
|
$28.88 K
|
$41.30 K
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
1
|
-61.15
|
-52.49
|
1
|
1
|
0
|
| Research and Development Expenses |
$10.21 M
|
$10.79 M
|
$11.52 M
|
$8.46 M
|
$7.35 M
|
$2.26 M
|
$1.59 M
|
$826.88 K
|
| General & Administrative Expenses |
$8.50 M
|
$9.56 M
|
$10.79 M
|
$9.45 M
|
$6.83 M
|
$1.25 M
|
$555.17 K
|
$222.05 K
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$238.95 K
|
$11.34 K
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$8.50 M
|
$9.56 M
|
$10.79 M
|
$9.68 M
|
$6.84 M
|
$1.25 M
|
$555.17 K
|
$222.05 K
|
| Other Expenses |
-$94.05 K
|
$0.00
|
$0.00
|
-$8.48 M
|
-$7.39 M
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$18.62 M
|
$20.35 M
|
$22.31 M
|
$9.67 M
|
$6.80 M
|
$3.51 M
|
$2.14 M
|
$1.05 M
|
| Cost And Expenses |
$18.71 M
|
$20.35 M
|
$22.31 M
|
$17.91 M
|
$13.96 M
|
$3.51 M
|
$2.14 M
|
$1.05 M
|
| Interest Income |
$244.39 K
|
$357.10 K
|
$494.23 K
|
$375.36 K
|
$12.50 K
|
$3.64 K
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$20.54 K
|
$52.48 K
|
| Depreciation & Amortization |
$94.05 K
|
$84.07 K
|
$83.58 K
|
$26.63 K
|
$15.48 K
|
$9.59 K
|
$2.57 K
|
$741.00
|
| EBITDA |
-$18.62 M |
-$20.27 M |
-$22.17 M |
-$17.76 M |
-$13.82 M |
-$3.47 M |
-$2.10 M |
-$1.03 M |
| EBITDA Ratio |
0
|
0
|
-401.77
|
-133.9
|
-103.2
|
-120.14
|
-50.79
|
-49.86
|
| Operating Income Ratio |
0
|
0
|
-403.28
|
-134.02
|
-103.24
|
-120.48
|
-50.85
|
-49.9
|
| Total Other Income/Expenses Net |
-$589.28 K
|
$476.22 K
|
$64.89 K
|
$279.28 K
|
-$60.43 K
|
-$92.85 K
|
-$86.22 K
|
-$67.44 K
|
| Income Before Tax |
-$19.30 M
|
-$19.87 M
|
-$22.19 M
|
-$17.50 M
|
-$13.89 M
|
-$3.57 M
|
-$2.19 M
|
-$1.10 M
|
| Income Before Tax Ratio |
0
|
0
|
-402.11
|
-131.92
|
-103.69
|
-123.69
|
-52.94
|
-53.17
|
| Income Tax Expense |
$861.12 K
|
$536.82 K
|
$79.28 K
|
$92.98 K
|
$4.01 K
|
$5.39 K
|
$7.11 K
|
$9.78 K
|
| Net Income |
-$20.16 M
|
-$20.41 M
|
-$22.27 M
|
-$17.59 M
|
-$13.89 M
|
-$3.58 M
|
-$2.19 M
|
-$1.11 M
|
| Net Income Ratio |
0
|
0
|
-403.54
|
-132.62
|
-103.72
|
-123.88
|
-53.11
|
-53.64
|
| EPS |
-0.61 |
-0.89 |
-1.71 |
-1.48 |
-1.37 |
-0.3 |
-0.37 |
-0.19 |
| EPS Diluted |
-0.61 |
-0.89 |
-1.71 |
-1.48 |
-1.37 |
-0.3 |
-0.26 |
-0.19 |
| Weighted Average Shares Out |
$32.97 M
|
$22.88 M
|
$13.01 M
|
$11.88 M
|
$10.17 M
|
$11.88 M
|
$8.37 M
|
$5.86 M
|
| Weighted Average Shares Out Diluted |
$32.97 M
|
$22.88 M
|
$13.01 M
|
$11.88 M
|
$10.17 M
|
$11.88 M
|
$8.37 M
|
$5.86 M
|
| Link |
|
|
|
|
|
|
|
|
